Patients struggle with lack of consistent coverage for popular weight-loss drugs
Supplies of high-demand obesity treatments are improving, but that doesn’t mean they’re easier to get.
Pharmaceutical
Articles
Lebanon planning board OKs design for Lilly Medicine Foundry at LEAP District
The foundry will give the pharmaceutical maker the ability to research new ways of producing medicines.
Trump casts psychiatric and weight-loss drugs as threats to children
President Donald Trump has instructed his administration to scrutinize the “threat” to children posed by antidepressants, stimulants and other common psychiatric drugs.
Could obesity drugs help with alcohol cravings? New study suggests potential.
The results add to evidence from animal studies and reports that people are finding the drugs helpful to manage cravings, not just for food, but also for tobacco and alcohol.
FDA approves non-opioid painkiller Journavx
The painkiller is the first novel pain drug to win government authorization in more than 20 years.
Purdue Pharma and owners to pay $7.4B in settlement over OxyContin’s toll
The deal represents an increase of more than $1 billion over a previous settlement deal that was rejected last year by the U.S. Supreme Court.
Sweeping review looks at effect of weight-loss drugs on 175 conditions
The research is the first to attempt to comprehensively investigate the impact—both good and bad—of the GLP-1 weight-loss drugs on the human body.
Indiana attorney general sues drug companies over EpiPen prices
The lawsuit alleges the price increases EpiPen, used to treat severe allergic reactions, prevented other similar medications to from going to market.
Lilly shares fall midday on lower fourth quarter revenue guidance
The company expects fourth-quarter revenue to be about $13.5 billion.
Lilly acquires Scorpion Therapeutics in deal worth up to $2.5B
The Indianapolis-based drugmaker will acquire Scorpion’s STX-478, a once-daily oral treatment in early trials for breast cancer and other advanced solid tumors.
Lilly sees new weight-loss pill approval in early 2026, CEO says
Pills would be more convenient for patients and also easier to manufacture at large scale than other top weight-loss drugs, which require , CEO Dave Ricks said.
U.S. ‘notorious markets’ report warns of risks from online pharmacies
The report says 96% of online pharmacies were found to be violating the law, many operating without a license and selling medicines without prescriptions and safety warnings.
FDA set to phase out leading decongestant in many cold medicines
Phenylephrine is used in popular versions of Sudafed, Dayquil and other medications, but experts have long questioned its effectiveness.
FDA approves Lilly’s Zepbound for obstructive sleep apnea
Lilly’s stock was up slightly in after-hours trading.
Lilly stock caught up in wave of uncertainty
After a stunning 703% run-up in price over the past five years, shares of Eli Lilly and Co. have been on a roller-coaster ride since September.
Lilly’s U.S. weight-loss drug shortage ends, curtailing copycats
The FDA had previously said Lilly’s drugs were out of shortage and that making copies must cease in October. Compounders sued, causing the FDA to pause enforcement while it reevaluated its decision.
Lilly CEO predicts obesity-treatment Zepbound will become drugmaker’s top drug by 2025
David Ricks told a lunch audience at the Economic Club of Washington, D.C., that Zepbound could quickly become the most popular drug in the 148-year-old company’s history.
Trial shows Lilly’s Zepbound helps patients lose far more weight than competing drug
Eli Lilly and Co. said its weight-loss treatment Zepbound helped patients lose 47% more relative weight than competitor Novo Nordisk’s obesity treatment Wegovy in a head-to-head clinical trial.
Trump efficiency guru Ramaswamy could benefit from crusade against FDA
Vivek Ramaswamy owns about $670 million in shares of Roivant Sciences, which is pursuing studies for three drugs that could land before the FDA during Donald Trump’s second term.
New FDA rules for TV drug ads: Simpler language and no distractions
TV remains the drug industry’s primary advertising format, with more than $4 billion spent in the past year, led by blockbuster drugs like weight-loss treatment Wegovy, according to ispot.tv, which tracks ads.